Results 81 to 90 of about 104,869 (316)

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

open access: yesDermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Sonja Ständer   +11 more
doaj   +1 more source

Nickel(II) sulphate–induced allergic contact dermatitis as experimental tool to investigate inflammatory pruritus in humans

open access: yesFrontiers in Allergy
Allergic contact dermatitis is a leading cause of occupational skin disease, with nickel(II) sulphate representing one of the most prevalent contact allergies worldwide.
Karoline Lukaschek   +6 more
doaj   +1 more source

Brachioradial Pruritus and Notalgia Paraesthetica: A Comparative Observational Study of Clinical Presentation and Morphological Pathologies

open access: yesActa Dermato-Venereologica, 2017
Brachioradial pruritus (BRP) and notalgia paraesthetica (NP) represent 2 of the most common neuropathic itch syndromes. A total of 58 consecutive patients presenting at the Center for Chronic Pruritus, University Hospital Münster, were analysed with ...
Manuel P. Pereira   +5 more
doaj   +1 more source

Chronic Pruritus in the Absence of Skin Disease: A Retrospective Study of 197 French Inpatients

open access: yesActa Dermato-Venereologica, 2020
Chronic pruritus (CP) can occur in the absence of skin diseases, and may be secondary to various causes. The aim of this study was to retrospectively analyse the causes of CP without skin disease in a cohort of patients from the dermatology department ...
Marine Robert   +2 more
doaj   +1 more source

Pathogenesis of pruritus [PDF]

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2011
SummaryThe pathogenesis of acute and chronic (> 6 weeks duration) pruritus is complex and involves in the skin a network of resident cells (e. g., mast cells, keratinocytes, sensory neurons) and transient inflammatory cells (e. g., eosinophils). Though pruritus and pain show overlapping mechanisms, recent studies have provided evidence that pruritus
Sonja, Ständer   +6 more
openaire   +2 more sources

Nalfurafine hydrochloride to treat pruritus: a review [PDF]

open access: yes, 2015
Shigeki InuiDepartment of Regenerative Dermatology, Osaka University Graduate School of Medicine, Osaka, JapanAbstract: Uremic pruritus has a great negative influence on quality of life in hemodialysis (HD) patients and, importantly, negatively affects ...
Inui S
core  

London Bridge is down

open access: yes, 2022
London Bridge is down * QRt by PRURITUS MIGRANS * CC: BY-NC ...
Pruritus Migrans
core   +1 more source

Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Intradermal application of lipopolysaccharide (LPS), a Toll‐like receptor 4 agonist, induces a local inflammatory response and is used as a human challenge model to evaluate the pharmacodynamics of investigational medicinal products. While currently applied in a single, parallel‐group setting, alternative within‐subject designs involving repeated ...
Alexandra A. J. Sillé   +12 more
wiley   +1 more source

Treatment Preferences Among Systemic Therapy-Naïve Patients with Atopic Dermatitis or Psoriasis in Germany: A Multicentre Study

open access: yesDermatology and Therapy
Introduction Despite the expanding range of approved systemic therapies for atopic dermatitis (AD) and psoriasis (PSO), data on patient preferences remain limited. It is largely unknown whether patients wish to initiate systemic treatment, which route of
Svenja Royeck   +7 more
doaj   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy